Haematology & Transfusion Science

POC data management

Radiometer Ltd has implemented its AQURE Enterprise point-of-care (POC) data management system at the University of Leicester Hospitals NHS Trust’s new Emergency Department.

Retinal photography to calculate risk

Scientists have discovered a new way to assess a person’s risk of heart disease using machine learning.

Does PSA screening save lives?

Inviting men with no symptoms to a one-off PSA test for prostate cancer does not save lives, according to results from the largest ever prostate cancer trial.

My lab: Braving the weather

Valerie Bocker, Specialist Biomedical Scientist from NHS Lothian, writes about the dedication of laboratory staff when snow struck.

Effectiveness of POCT

Associate Professor in Biomedical Sciences Paul Waller questions some of the assumptions made about point-of-care testing.

Cancer screening revolution?

A new US-developed blood test could help detect eight common cancers before they spread.

The Lutheran blood group system

The Lutheran blood group system (BGS) consists of a large number of antigens, 24 being recognised by the International Society of Blood Transfusion at the time of writing, and is also of interest in terms of the various backgrounds to the (apparent) Lu(a-b-) phenotypes. The Lutheran BGS is also incorrectly named, as will be explained shortly.

Registration as a Clinical Scientist

Alan Wainwright, IBMS Executive Head of Education, explains why the Institute has launched a new experiential route to registration as a Clinical Scientist.

Meet the President

New IBMS President Alison Geddis discusses pride in her profession, belief in the work of the IBMS and desire to see biomedical scientists recognised for the vital role they play.

"We see people, not blood tubes"

Malcolm Robinson, co-founder of Harvey’s Gang, tells how allowing children into pathology labs is transforming their healthcare experiences – and those of the staff who meet them.

Blood cancer trial participants

People aged 75 years and older are under-represented in blood cancer clinical trials, according to a comprehensive analysis of clinical trial.

Top